Monday, February 15, 2021

Metformin may help in reducing the risk for Macular Degeneration

In a large case-control study using a national database of patients, metformin use was associated with reduced odds of developing age-related macular degeneration (AMD). This association was dose dependent, with the greatest benefit at low to moderate doses. When looking only at patients with diabetes, the authors note preservation of the dose-dependent decrease in the odds of patients developing AMD. Metformin does not appear to be protective in patients with diabetes and coexisting diabetic retinopathy. This study suggests that metformin may be useful as a preventive therapy for AMD and provides the basis for potential prospective clinical trials.

In the US, AMD is the leading cause of irreversible blindness in adults older than 50 years. As the older adult population increases worldwide, there is a growing economic burden of AMD. Currently, there are no efficacious preventive measures for AMD development or available treatments for the nonexudative form, which accounts for 90% of cases.

Metformin, the most commonly prescribed oral antihyperglycemic drug for diabetes, has been shown to have antiaging and protective effects against many age-associated diseases. In epidemiology studies, metformin lowers the risk of developing cardiovascular disease, stroke, cancer, dementia, and primary open-angle glaucoma. Metformin also reduces inflammatory markers and increases life span in murine models. These exciting findings have led to the Targeting Aging With Metformin (TAME) trial, a prospective randomized clinical trial to assess metformin’s antiaging effects.

Given the known antiaging effects of metformin and its relatively safe adverse-effect profile, the authors of this study sought to determine if the use of metformin is associated with reduced odds of developing AMD in a large, nationwide sample. They also investigated a potential dose-dependent association in the study population, as well as in a subgroup of only patients with diabetes. Additionally, the authors evaluated whether the findings were dependent on the presence or absence of coexisting diabetic retinopathy (DR).

Since you’re here...we have a small favor to ask. Retina Global is a nonprofit, and we have to depend on your support to sustain the work we do. Hence the need to ask for your help. Retina Global's work is important, since it not only provides help to disadvantaged people, but also provides resources for developing new treatments that can potentially cure blindness. What we do takes a lot of time, money and hard work. But we do it because we believe we have to help stop someone somewhere from going blind. So make a difference. Click here to donate. Your support is much appreciated. Thank you!

The authors found that not only does metformin reduce the odds of developing AMD, but that this outcome is strongest at low to moderate doses and is only seen in the absence of coexisting DR. This study highlights metformin as a possible therapeutic intervention to prevent or slow the progression of AMD. The authors add that future studies will be important to further validate and confirm this finding, in addition to determining the molecular mechanisms involved and which pathogenic pathways of AMD are affected by metformin. If a protective effect of metformin is confirmed in clinical trials, they believe this may lead to a novel therapeutic strategy for this disease, which is the leading cause of blindness in older adults and has no previously established preventive measures.

To read more about the study, click here

More about Retina Global here. We seek your support. Click here to donate.

No comments:

Post a Comment

Thanks for your comments. We will get back to you shortly if there is a need to respond to it.

- Admin, Retina Global
Read more on Retina Global.